BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 29938543)

  • 1. Biological therapies for eosinophilic asthma.
    Patel SS; Casale TB; Cardet JC
    Expert Opin Biol Ther; 2018 Jul; 18(7):747-754. PubMed ID: 29938543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update.
    Walsh GM
    Expert Opin Biol Ther; 2020 Oct; 20(10):1237-1244. PubMed ID: 32529893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on reslizumab for eosinophilic asthma.
    Cardet JC; Israel E
    Expert Opin Biol Ther; 2015; 15(10):1531-9. PubMed ID: 26372797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
    Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
    Hillas G; Fouka E; Papaioannou AI
    Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
    Matera MG; Calzetta L; Rinaldi B; Cazzola M
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):1007-1013. PubMed ID: 28737051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advancements in biologic therapy in eosinophilic asthma.
    Patadia R; Casale TB; Fowler J; Patel S; Cardet JC
    Expert Opin Biol Ther; 2024 Apr; 24(4):251-261. PubMed ID: 38619468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgE and eosinophils as therapeutic targets in asthma.
    Patel TR; Sur S
    Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma.
    Pelaia C; Calabrese C; Vatrella A; Busceti MT; Garofalo E; Lombardo N; Terracciano R; Pelaia G
    Biomed Res Int; 2018; 2018():4839230. PubMed ID: 29862274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab.
    Jackson DJ; Korn S; Mathur SK; Barker P; Meka VG; Martin UJ; Zangrilli JG
    Drug Saf; 2020 May; 43(5):409-425. PubMed ID: 32242310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benralizumab for the treatment of asthma.
    Saco TV; Pepper AN; Lockey RF
    Expert Rev Clin Immunol; 2017 May; 13(5):405-413. PubMed ID: 28379047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
    Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
    Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
    Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
    Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
    J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Targeted Therapies for Uncontrolled Asthma.
    Corren J
    J Allergy Clin Immunol Pract; 2019; 7(5):1394-1403. PubMed ID: 31076057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.
    Cazzola M; Matera MG; Levi-Schaffer F; Rogliani P
    Expert Opin Drug Saf; 2018 Apr; 17(4):429-435. PubMed ID: 29486600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-4/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma.
    Wu AY; Sur S; Grant JA; Tripple JW
    Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):30-37. PubMed ID: 30407206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.